Baird Downgrades AMAG Pharmaceuticals (AMAG) to Neutral; Stepping To Sidelines As Risk Profile Increases

Baird downgraded AMAG Pharmaceuticals (NASDAQ: AMAG) to Neutral with a new price target of $17.00.

Analyst, Christopher Raymond, said, "While take-out was by no means our sole investment thesis, AMAG's new direction - switching roles from acquired to acquirer - introduces new elements of risk in that M&A as often as not can harm shareholder value, despite every good intention. While we do like where Feraheme seems headed, and are intrigued by this directional change, we would prefer to watch this company's evolution from the sidelines, at least for the time being."

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $16.02 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• CAE Inc. (CAE:CN) (CAE) PT Raised to Cdn$49 at Desjardins
• Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins